ANTHRACYCLINE TOPOISOMERASE II INHIBITOR
Ellence is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat people with axillary node tumor involvement after removal of primary breast cancer. Ellence may be also referred to by its drug name, epirubicin hydrochloride.
Ellence is an anthracycline topoisomerase II inhibitor. Ellence is believed to fight breast cancer by interfering with cancer cells’ ability to divide.
How do I take it?
Ellence is generally administered intravenously on one or two days of a three- to four-week cycle.
Ellence comes in the form of an injectable solution.
The FDA-approved label for Ellence lists common side effects including low blood counts, loss of a menstrual period, nausea or vomiting, tiredness, diarrhea, infection, hair loss, rash, conjunctivitis, and skin changes.
Rare but serious side effects listed for Ellence include heart damage, secondary cancer (acute myelogenous leukemia), tissue necrosis, blood clots, and fetal harm in pregnant women.
For more details about this treatment, visit:
Ellence — RxList
Ellence — Chemocare.com